When to Use Breast Cancer Classification with PCA + Logistic Regression

You're staring at 30 measurements from a fine-needle aspirate biopsy of a breast mass: radius, texture, perimeter, area, smoothness, compactness—each captured as mean, standard error, and worst value. Your job is to predict whether the tumor is malignant or benign. The pathologist needs an answer. And here's the problem: those 30 features are correlated. Radius and perimeter move together. Area tracks with radius squared. Compactness and concavity overlap. Feed them all into logistic regression and your coefficients will swing wildly with minor dataset changes—that's multicollinearity breaking your model.

This is where breast cancer classification with PCA + logistic regression becomes the right tool. The Wisconsin Diagnostic Breast Cancer dataset contains 569 tumor samples with 30 numeric features describing cell nucleus morphology from digitized biopsy images. Principal Component Analysis (PCA) reduces those correlated features to 2-3 orthogonal components that capture 90%+ of the variance. Then logistic regression builds a stable, interpretable binary classifier: malignant or benign. The model achieves AUC > 0.96 when properly validated—but only if you handle class imbalance, select the right decision threshold, and understand which features actually drive the diagnosis.

This article walks through the experimental setup, PCA dimensionality reduction, logistic regression training, and performance evaluation. We'll analyze the actual confusion matrix, ROC curve, and feature coefficients from a real classification model. Before we draw conclusions about what predicts malignancy, let's check the experimental design: is the dataset balanced? Are PC1 and PC2 sufficient? Did we validate on held-out data? Here's how to set up a proper breast cancer classification experiment.

Why This Classification Problem Requires Dimensionality Reduction

The Wisconsin breast cancer dataset was created by analyzing digitized images of fine-needle aspirates (FNA) from breast masses. For each cell nucleus in the image, researchers computed 10 real-valued features: radius (mean distance from center to perimeter), texture (standard deviation of gray-scale values), perimeter, area, smoothness (local variation in radius), compactness (perimeter² / area - 1.0), concavity (severity of concave portions), concave points (number of concave portions), symmetry, and fractal dimension. Then for each of those 10 measurements, they calculated the mean, standard error (SE), and worst (largest) value across all nuclei, producing 30 features total.

The problem: these features are not independent. Radius and perimeter are geometrically related (perimeter ≈ 2πr for circular nuclei). Area scales with radius squared. Compactness is a function of perimeter and area. Feed all 30 into logistic regression and you get coefficient instability: a model trained on 500 samples might assign weight +3.2 to mean_radius and -2.8 to mean_perimeter, but retrain on a bootstrap sample and those coefficients flip. That's multicollinearity: when predictors are correlated, small data changes cause large coefficient changes. The predictions might stay stable, but you lose interpretability—you can't say "larger radius increases malignancy risk by X%" when the radius coefficient depends on which other features made it into the model.

PCA solves this by rotating the 30-dimensional feature space into orthogonal principal components ranked by variance explained. PC1 is a weighted combination of all 30 features that captures the direction of maximum variance in the data. PC2 is orthogonal to PC1 and captures the next-largest variance. By construction, principal components are uncorrelated. When you run logistic regression on PC1, PC2, and PC3 instead of the raw features, you get stable coefficients and a clear interpretation: "a one-unit increase in PC1 (which loads heavily on size-related features) increases log-odds of malignancy by β₁."

The Experimental Setup: What We're Testing

Here's the research question: Can a logistic regression model trained on principal components of cell nucleus morphology features classify breast tumors as malignant or benign with AUC ≥ 0.95 and sensitivity ≥ 0.95?

The null hypothesis is that cell nucleus features provide no diagnostic information (AUC = 0.5, equivalent to random guessing). The alternative hypothesis is that malignant and benign tumors have systematically different nucleus morphology, making them linearly separable in PCA space.

The experiment follows this protocol:

1. Data: 569 tumor samples, each labeled M (malignant) or B (benign) by expert pathologists. This is the ground-truth diagnosis.
2. Split: 70% training (398 samples), 30% test (171 samples). Stratified by diagnosis class to preserve the ~63% benign / 37% malignant ratio in both sets.
3. Preprocessing: Standardize the 30 features on the training set (z = (x - μ_train) / σ_train). Apply the same transformation to the test set using training μ and σ.
4. PCA: Fit PCA on the training set. Determine the number of components needed to explain 90% of variance. Transform both train and test data.
5. Logistic regression: Train a logistic regression classifier on the principal components. Use L2 regularization (ridge) with cross-validation to select the regularization strength.
6. Evaluation: On the held-out test set, compute predicted probabilities, plot the ROC curve, calculate AUC, and generate the confusion matrix at the optimal threshold.

Crucially, we did not tune the decision threshold on the test set—that would overfit. Instead, we used the training set to identify the threshold that maximizes Youden's J statistic (sensitivity + specificity - 1), then applied that threshold to the test set. For cancer diagnosis, we'll also examine thresholds that achieve sensitivity ≥ 0.95, because missing a malignant tumor (false negative) has far greater clinical cost than a false positive.

Diagnosis Class Distribution

The bar chart shows 357 benign (B) tumors and 212 malignant (M) tumors in the full dataset—a 62.7% / 37.3% split. This is mild class imbalance. It's not severe enough to require SMOTE upsampling or random undersampling, both of which introduce their own biases. Instead, the proper approach is to train logistic regression with class_weight='balanced', which automatically assigns higher loss weight to the minority class (malignant) during training. This tells the optimizer "penalize false negatives more heavily than false positives," which is exactly what we want in cancer diagnosis.

Why does class imbalance matter? If you train a naive classifier on this dataset without weighting, it could achieve 62.7% accuracy by predicting "benign" for every sample—never once identifying a malignant tumor. Accuracy is a misleading metric when classes are imbalanced. That's why we'll evaluate this model using AUC (area under the ROC curve), sensitivity (recall for malignant cases), and specificity (recall for benign cases). A clinically useful model must achieve high sensitivity—ideally ≥ 0.95, meaning it catches 95%+ of malignant tumors even if that means more false positives.

The distribution also tells us we have adequate sample size for both classes. With 212 malignant tumors and 30 features, we're well above the 10-events-per-variable guideline for logistic regression (10 × 30 = 300 events). However, after PCA, if we retain only 3 components, we're modeling with 3 predictors, so even 212 malignant cases gives us 70 events per variable—very comfortable margin against overfitting.

One methodological note: we used stratified train-test splitting to preserve this 63/37 ratio in both the training and test sets. If you split randomly without stratification, you might end up with 70% benign in training and 55% benign in test, which would bias your performance estimates. Always stratify by the outcome variable in classification experiments.

PCA Biplot — PC1 vs PC2 by Diagnosis

The scatter plot shows every tumor projected onto the first two principal components, with benign tumors in blue and malignant in red. The key finding: the classes are linearly separable in this 2-D space. Benign tumors cluster in the lower-left quadrant (negative PC1, near-zero PC2), while malignant tumors spread across positive PC1 values. You could draw a diagonal line through this plot that correctly classifies 90%+ of tumors—and that's exactly what logistic regression will do.

What does PC1 represent? It's a weighted combination of all 30 features, but you can interpret it by examining the loadings (which features contribute most to PC1). In this dataset, PC1 loads heavily on size-related features: mean radius, mean perimeter, mean area, worst radius, worst perimeter, worst area. Malignant tumors have larger, more irregular nuclei, so they score higher on PC1. PC2 captures variance orthogonal to size—it tends to load on texture, smoothness, and symmetry. The biplot shows that PC2 alone doesn't separate the classes well (there's vertical overlap), but PC1 does most of the classification work.

This visual is the first evidence that our hypothesis is correct: cell nucleus morphology does contain diagnostic information. If benign and malignant tumors were randomly scattered with complete overlap, PCA + logistic regression would fail. The fact that they cluster into distinct regions tells us the problem is solvable. However, notice the handful of red points (malignant) in the benign cluster and vice versa—those are the cases our model will struggle with. No linear classifier is perfect when the classes aren't 100% separable.

One experimental validation check: this biplot was generated using the full dataset for visualization, but the PCA transformation was fit on the training set only. When we evaluate model performance, we'll use test set projections onto the training PCA components. Fitting PCA on the full dataset before splitting would leak information from the test set into the training process, inflating performance estimates.

Scree Plot — Variance Explained per PC

The scree plot shows variance explained by each of the first 10 principal components. PC1 alone captures ~44% of total variance—nearly half the information in 30 features compressed into a single dimension. PC2 adds another ~19%, bringing cumulative variance to ~63%. PC3 contributes ~9%, reaching ~72% cumulative. By the time you reach PC5, you're explaining 85%+ of variance, and the curve flattens into the "scree" (the rubble at the base of a cliff).

How many components should you retain? There's no universal rule, but here are three methods:

• Elbow method: Look for the "elbow" where the curve flattens. In this plot, the elbow is around PC3-4. Beyond that, each component adds < 5% marginal variance.
• Cumulative variance threshold: Retain enough components to explain 90% of variance. Here, that's ~7 components.
• Cross-validation: Train logistic regression with 1, 2, 3, … components and measure test-set AUC. Stop when AUC stops improving. This is the most rigorous approach.

In practice, this model uses the first 3 principal components for classification. Why not all 30? Because the later components capture noise, not signal. PC20 might explain 0.3% of variance—that's measurement error and random fluctuation. Including it increases model complexity (more parameters to estimate) without improving predictions. It also reintroduces the multicollinearity problem PCA was supposed to solve: if you use all 30 PCs, you've just rotated the feature space without reducing dimensionality.

The scree plot also validates that PCA is appropriate for this dataset. If the variance were evenly distributed across all 30 components (~3.3% each), PCA wouldn't help—there would be no low-dimensional structure to exploit. The steep drop-off from PC1 to PC10 confirms that the 30 features are redundant and can be compressed.

Logistic Regression Coefficients

The horizontal bar chart shows the logistic regression coefficients for each principal component. PC1 has a large positive coefficient (approximately +2.8), meaning higher PC1 scores strongly increase the log-odds of malignancy. Remember from the biplot: PC1 loads on size-related features (radius, perimeter, area). This coefficient tells us "larger nuclei → higher probability of malignancy," which aligns with clinical knowledge. Malignant cells have irregular, enlarged nuclei compared to benign cells.

PC2 has a smaller positive coefficient (~+0.6). PC2 captures texture and smoothness variation orthogonal to size. The positive sign suggests that certain texture patterns (high standard deviation of gray-scale values, irregular smoothness) also correlate with malignancy, though less strongly than size. PC3's coefficient is near zero (~-0.1), indicating it contributes little to the classification decision. This matches the scree plot: PC3 explains only 9% of variance, and that variance isn't aligned with the benign/malignant distinction.

Why does PC1 dominate? Because it captures the axis of maximum variance and that axis happens to align with the class boundary. If malignant and benign tumors differed primarily in texture (PC2) rather than size (PC1), PC2 would have the larger coefficient. The fact that PC1 is both the largest variance component and the strongest predictor is a lucky coincidence—it makes the model highly interpretable. "Bigger nuclei mean cancer" is a message clinicians can trust because it matches their domain knowledge.

One technical note: these coefficients are for standardized principal components. Because we z-scored the original features before PCA, each PC has mean 0 and standard deviation 1. A one-unit increase in PC1 means moving one standard deviation along that component. If you didn't standardize, the coefficient magnitudes would depend on arbitrary feature scales (area measured in pixels² vs. smoothness measured in 0-1 range), and you couldn't compare them meaningfully.

ROC Curve

The ROC (Receiver Operating Characteristic) curve plots true positive rate (sensitivity) on the y-axis against false positive rate (1 - specificity) on the x-axis, sweeping the classification threshold from 0 to 1. The area under this curve (AUC) is 0.99—near-perfect discrimination. An AUC of 0.5 means random guessing (the diagonal dashed line); AUC = 1.0 means perfect separation. At 0.99, this model ranks malignant tumors higher than benign tumors 99% of the time.

But AUC alone doesn't tell you which threshold to use. The default 0.5 threshold (predict malignant if P(malignant) > 0.5) is arbitrary and often wrong. For cancer diagnosis, you care about sensitivity: what fraction of actual malignant tumors does the model catch? The ROC curve shows that at a threshold yielding 95% sensitivity (0.95 true positive rate), the false positive rate is approximately 0.03 (3%). In other words, you can detect 95% of malignant cases while only misclassifying 3% of benign cases as malignant.

Oncologists would likely prefer even higher sensitivity—perhaps 98% or 99%. Reading from the curve, achieving 99% sensitivity increases the false positive rate to ~8%. That's a trade-off decision: is it acceptable to send 8 out of 100 benign patients for additional testing (biopsy confirmation, imaging) in order to catch 99 out of 100 malignant cases? In cancer diagnosis, the answer is almost always yes. False positives cause anxiety and additional procedures, but false negatives mean untreated cancer.

The ROC curve also reveals where the model struggles. The curve rises steeply from (0,0) to (~0.02, 0.90), indicating that most malignant tumors have very high predicted probabilities—easy classifications. The final climb from 0.95 to 1.0 sensitivity is slower, showing that the last 5% of malignant cases are harder to distinguish from benign. Those are the tumors sitting in the overlap region of the PCA biplot: small malignant tumors or large benign tumors with ambiguous features.

Confusion Matrix

The confusion matrix shows predictions on the held-out test set (171 samples) at the threshold chosen to maximize Youden's J statistic on the training set. The numbers are stark: 106 true negatives (benign correctly classified), 63 true positives (malignant correctly classified), 1 false positive (benign misclassified as malignant), and 1 false negative (malignant misclassified as benign).

Let's calculate the performance metrics. Sensitivity (true positive rate, recall for malignant class) = 63 / (63 + 1) = 0.984. The model catches 98.4% of malignant tumors. Specificity (true negative rate, recall for benign class) = 106 / (106 + 1) = 0.991. It correctly identifies 99.1% of benign tumors. Precision (positive predictive value) = 63 / (63 + 1) = 0.984. When the model predicts malignant, it's correct 98.4% of the time.

The critical cell is the false negative: 1 malignant tumor misclassified as benign. In a clinical setting, that patient would be told "your biopsy is benign, no treatment needed" when in fact they have cancer. This is why we emphasized sensitivity in the ROC analysis. If you lower the threshold from the Youden-optimal value, you can drive false negatives to zero—but you'll increase false positives. The false positive (1 benign tumor called malignant) triggers additional workup: the patient undergoes surgical biopsy or lumpectomy, which reveals benign tissue. That's stressful and costly, but not life-threatening.

What happened with the false negative case? We can't see individual data points here, but based on the PCA biplot, it's likely a malignant tumor with small nuclei (low PC1 score) that fell into the benign cluster. This is a fundamental limitation of linear classifiers: when classes overlap, there's no threshold that achieves 100% sensitivity and 100% specificity simultaneously. You have to choose where to put the decision boundary, and that choice encodes a value judgment about the relative costs of false positives vs. false negatives.

For model deployment, you'd report both the confusion matrix at a specified threshold and the full ROC curve, allowing clinicians to select their preferred operating point. Some might accept 95% sensitivity; others might demand 99%. The ROC curve gives them the data to make that call.

How to Interpret Your Results

You've run the analysis on your own biopsy dataset. You have PCA biplots, scree plots, logistic regression coefficients, an ROC curve, and a confusion matrix. Here's how to interpret each component and decide whether the model is ready for validation or needs refinement.

Step 1: Check Class Balance

Look at the diagnosis distribution. If one class is < 10% of the data, you have severe imbalance—use class weighting or consider resampling methods. If both classes have ≥ 50 samples, you have enough data for stable estimates. If the minority class has < 30 samples, your model will struggle to generalize; collect more data or switch to a simpler model (e.g., decision tree with fewer splits).

Step 2: Validate PCA Separation

Examine the PCA biplot. Do the classes form distinct clusters, or is there complete overlap? If they're well-separated, linear classifiers (logistic regression, linear SVM) will work. If they overlap heavily, you may need nonlinear methods (kernel SVM, random forest) or additional features. Check PC1 loadings: do the top-loading features make clinical sense? If PC1 is dominated by a single feature, that feature alone might be sufficient—skip PCA and use univariate logistic regression.

Step 3: Choose the Number of Components

Use the scree plot and cross-validation. Retain components until cumulative variance ≥ 90% or until test-set AUC stops improving. Don't use all 30 components—you'll overfit. For visualization, always plot PC1 vs PC2. For classification, 3-5 components is typical. If AUC with 3 components is 0.96 and AUC with 10 components is 0.97, stick with 3—the marginal gain isn't worth the complexity.

Step 4: Interpret Coefficients

Which principal components have large coefficients? Do they align with clinical knowledge? If PC1 (size) has a large positive coefficient and PC2 (texture) is near zero, the model is saying "size matters, texture doesn't." Validate this against pathology literature. If a component with a large coefficient has low variance explained (e.g., PC8), question whether it's signal or overfitting.

Step 5: Set the Threshold Using the ROC Curve

Don't use 0.5. For cancer diagnosis, target sensitivity ≥ 0.95 or ≥ 0.98. Find the threshold on the ROC curve that achieves your required sensitivity, then check the corresponding specificity. If you need 98% sensitivity and that gives you 70% specificity, you'll have 30% false positives—is that acceptable? Consult with clinicians. Document the chosen threshold and the rationale.

Step 6: Validate the Confusion Matrix

At your chosen threshold, how many false negatives are there? In a test set of 171 samples with 64 malignant, even 1 false negative is 1.6% of malignant cases missed. Scale that to 10,000 patients: 160 missed cancers. Is that acceptable? If not, lower the threshold. Count false positives: in 107 benign cases, 1 false positive is 0.9%. Scale to 10,000: 90 unnecessary biopsies. Weigh the costs.

Common Mistakes and How to Avoid Them

Fitting PCA on the full dataset before train/test split. This leaks information from the test set into the training process. The test set statistics (mean, variance, covariance) influence the PCA rotation, so your test-set performance estimate is overly optimistic. Always fit PCA on the training set, then transform the test set using the training PCA.

Forgetting to standardize features before PCA. PCA maximizes variance, so features with large numeric ranges (e.g., area in pixels²) dominate components even if they're not the most informative. Standardize every feature to mean 0, standard deviation 1 before PCA. Use the training set's mean and SD for both train and test transformations.

Using accuracy as the performance metric. With 63% benign cases, a model that predicts "benign" for every sample gets 63% accuracy and 0% sensitivity. Accuracy hides failure. Use AUC, sensitivity, specificity, precision, and F1-score. For cancer diagnosis, prioritize sensitivity.

Accepting the default 0.5 threshold. The threshold that maximizes accuracy or Youden's J is not necessarily the threshold that minimizes clinical harm. For cancer, you want sensitivity ≥ 0.95 or ≥ 0.98, even if specificity drops. Use the ROC curve to choose the threshold that aligns with your cost function.

Interpreting PCA loadings without domain knowledge. Just because PC1 loads heavily on "worst concave points" doesn't mean that feature causes malignancy. PCA is a descriptive technique—it finds variance, not causation. Validate PCA-derived insights against pathology literature before making clinical claims.

Retaining too many or too few components. Using all 30 PCs defeats the purpose of dimensionality reduction and reintroduces multicollinearity. Using only PC1 discards 55% of variance. Use cross-validation: train models with 1, 2, 3, … components and plot test AUC vs. number of components. Retain the smallest number that achieves near-maximum AUC.

When PCA + Logistic Regression Is the Right Tool

This method is ideal when you have:

• Many correlated features: Morphology measurements (size, shape, texture) tend to correlate. Gene expression data, sensor arrays, and image features all benefit from PCA's orthogonalization.
• Binary classification: Logistic regression models the log-odds of one class vs. the other. For multi-class problems, use multinomial logistic regression or one-vs-rest.
• Linear decision boundaries: If the PCA biplot shows classes separated by a straight line (or plane in 3D), logistic regression will work. If the boundary is curved, try kernel PCA or nonlinear classifiers.
• Need for interpretability: Logistic regression coefficients tell you which components matter and in which direction. Random forests and neural nets may achieve slightly higher AUC but at the cost of interpretability.
• Modest sample size: With 500-5000 samples, logistic regression is stable and well-powered. For 100,000+ samples, consider regularized methods (elastic net) or ensemble models. For < 200 samples, validate with bootstrap or leave-one-out CV.

When not to use this approach:

• Features are already orthogonal: If you have uncorrelated predictors (e.g., age, BMI, blood pressure from different systems), skip PCA—it won't help and may hurt interpretability.
• Nonlinear relationships: If malignant tumors are characterized by extreme values (very small or very large nuclei), a linear model will miss the pattern. Try polynomial features, kernel SVM, or tree-based methods.
• Categorical or mixed features: PCA requires continuous numeric features. If you have categorical variables (tumor type: ductal, lobular, medullary), one-hot encode them, but be cautious—PCA on binary indicators often produces uninterpretable components.
• Sparse data: If 90% of your feature matrix is zeros (e.g., gene expression with many unexpressed genes), use sparse PCA or skip PCA entirely—standard PCA will dilute the signal.

Extending the Model: What to Try Next

Once you have a working PCA + logistic regression baseline (AUC > 0.95), here are ways to improve or validate it:

Regularization: Add L1 (lasso) or L2 (ridge) penalties to logistic regression. This shrinks coefficients toward zero, reducing overfitting. Use cross-validation to select the penalty strength. L1 can drive some coefficients exactly to zero, performing feature (component) selection.

Polynomial features: Create PC1², PC1×PC2, etc., before logistic regression. This allows the decision boundary to curve. Check if test AUC improves—if not, you're overfitting.

Ensemble methods: Train a random forest or gradient boosting classifier on the principal components. These can capture nonlinear interactions PCA + logistic regression misses. Compare test AUC: if random forest gives 0.97 vs. 0.96 for logistic regression, the gain may not justify the loss of interpretability.

Threshold tuning: Use the training set to build a grid of thresholds (0.1, 0.2, …, 0.9) and compute sensitivity, specificity, and F1 at each. Plot sensitivity vs. threshold and specificity vs. threshold. Identify the threshold that meets your sensitivity requirement with maximum specificity.

External validation: Test the model on a completely independent dataset from a different hospital or imaging system. AUC often drops 5-10% on external data due to distribution shift (different patient demographics, different FNA protocols). If AUC < 0.85 externally, recalibrate or retrain.

Calibration: Check if predicted probabilities match observed frequencies. Bin predictions into deciles (0-10%, 10-20%, …, 90-100%) and plot observed malignancy rate vs. predicted probability. If the model is well-calibrated, the points lie on the diagonal. If not, apply Platt scaling or isotonic regression to recalibrate.

FAQ: Breast Cancer Classification with PCA + Logistic Regression

Why use PCA before logistic regression for breast cancer classification?

The Wisconsin breast cancer dataset contains 30 highly correlated features (mean, SE, and worst values for 10 cell nucleus measurements). PCA eliminates multicollinearity, stabilizes logistic regression coefficients, and makes the model more interpretable by identifying orthogonal components that capture variance across related features. Without PCA, coefficients swing wildly with small data changes, making the model unreliable.

What AUC score indicates a clinically useful breast cancer classifier?

For cancer diagnosis, aim for AUC ≥ 0.95. The cost of false negatives (missing malignant tumors) is extremely high, so sensitivity should be maximized even at the expense of specificity. A model with AUC < 0.90 requires additional features, better feature engineering, or ensemble methods before clinical validation. The Wisconsin dataset achieves AUC ~ 0.99 with PCA + logistic regression, indicating excellent discrimination.

How many principal components should I use for tumor classification?

Check the scree plot. Typically 2-3 components capture 85-95% of variance in cell nucleus morphology data. Use the elbow method: retain components until cumulative variance plateaus. For visualization, use PC1 vs PC2. For classification, retain enough components to preserve 90%+ variance while avoiding overfitting on small datasets. Cross-validate: train models with 1, 2, 3, … components and choose the number that maximizes test-set AUC.

Should I balance the benign/malignant class distribution before training?

The Wisconsin dataset is 63% benign, 37% malignant—mild imbalance. For logistic regression, use class_weight='balanced' instead of resampling. Downsampling discards benign examples and reduces statistical power. Upsampling (SMOTE) can introduce artificial patterns. Weighted loss functions preserve all data while penalizing minority-class errors appropriately, which is the correct approach for medical diagnosis.

What threshold should I use for binary classification in cancer diagnosis?

The default 0.5 threshold is wrong for cancer detection. Plot the ROC curve and identify the threshold that achieves 95%+ sensitivity (recall for malignant class). In practice, oncologists prefer sensitivity ≥ 0.98 even if it means specificity drops to 0.85. False negatives are deadly; false positives trigger additional testing but save lives. Use the ROC curve to find the threshold that meets your sensitivity target with maximum specificity.

Run This Analysis on Your Own Data

You have tumor biopsy data—morphology measurements from FNA, imaging features, or gene expression panels. You need to classify samples as malignant or benign, and you need an interpretable model that clinicians can trust. MCP Analytics automates the entire pipeline: upload your CSV, specify the diagnosis column, and get PCA biplots, logistic regression coefficients, ROC curves, confusion matrices, and threshold recommendations in under 60 seconds.

The platform handles feature standardization, train/test splitting, PCA fitting, cross-validation, and performance metrics automatically. You get an interactive report showing which features load on each principal component, which components predict malignancy, and where the decision boundary should be for your required sensitivity. No coding, no setup—just upload and analyze.

Before you draw conclusions about which features predict cancer in your data, check the experimental design: Did you stratify by diagnosis class? Did you fit PCA on training data only? Did you validate on held-out samples? The difference between a publishable classifier and a flawed one often comes down to methodology. Here's how to set up a proper experiment—and MCP Analytics ensures you follow best practices every time.